Navigation Links
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Date:8/14/2008

nce 321: 974-977 (2008)

About Science

Founded in 1880 on $10,000 of seed money from the American inventor Thomas Edison, Science has grown to become the world's leading outlet for scientific news, commentary and cutting-edge research, with the largest paid circulation of any peer-reviewed general-science journal. Through its print and online incarnations, Science reaches an estimated worldwide readership of more than one million. In content, too, the journal is truly international in scope; some 35 to 40 percent of the corresponding authors on its papers are based outside the United States. Its articles consistently rank among world's most cited research.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is blinatumomab (MT103/MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical trial in patients with advanced non-Hodgkin's lymphoma. MT110,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , STREAMWOOD, Ill., Dec. 4 Sha...RI and PET/CT systems and service programs for hos...ounce it has received The Joint Commission,s Accre...recognized, prestigious gold seal of approval for ... accreditation is system-wide for its mobile MRI a...
(Date:12/4/2009)... , , LAKE FOREST, Ill., Dec. 4 /PR...), a leading global specialty pharmaceutical and m...unch of its next-generation 50 mL and 100 mL VisIV... and solutions, and now offers a complete size ran...tally responsible VisIV product. The launch of the...
(Date:12/4/2009)... , SAN DIEGO, Calif., Dec. 4 S...device company, today announced the appointment of...al Officer. In this role, Mr. Ranker will lead al...tions including finance, accounting, IT, IR, admin... on the Company,s senior management team. ,, "...
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 1SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 2SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 3Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 1Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 2Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 1OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 2OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 4OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 5
... In response,to recent media speculation regardin... (NDA), Daiichi Sankyo Company, Limited (TSE: 4568...ed today that they continue to have,discussions wi...n. The,companies have not been notified of any reg...or of any decision to have an advisory committee t...
...tional study,presented earlier today at the 2008 A...s, a researcher reported that "women under 40 year...44 percent more likely to die than,older women." A...rofessor,of surgery, Washington University School ...similar size tumor and lymph node status. The,char...
Other Medicine Technology:Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application 2Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application 3Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women 2Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women 3Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women 4
(Date:12/4/2009)...Dec. 4 The Editorial Advisory and ...gazine today announced Allergan, Inc. (NYSE: ....R. Bard, Inc. (NYSE: BCR ) as its February 201... and educational use. ,, "The committee chose A...its flagship drug Botox and other products as well...
(Date:12/4/2009)... that muscle cells grown in the lab can restore an... work, performed in dogs and rats, might ultimatel...ric reflux and fecal incontinence. , This techni...e the bands of muscle that separate the major sect...reas can cause gastrointestinal esophageal reflux ...
(Date:12/4/2009)... phenomenon that was started by people that were l...tal work in the US, Canada, and other countries. I...e have found that Mexican Dental Vacation is a gre... (PRWEB) December 4, 2009 -- Af...an Dental Vacation is seeing their best year ever,...
(Date:12/4/2009)...ic Effort but Points out Potential Risk if America...re Reform ,, NEW YORK, Dec. 4 /PRNewswire-USN... today published a Perspective opinion piece addr...dlener, M.D., president, Children,s Health Fund an...ess and Professor of Clinical Population & Fam...
(Date:12/4/2009)...to take breast cancer drug, study finds , ...ut side effects are a major reason why only 6 perc...er are willing to take the drug tamoxifen to preve...rt to inform women about the risks and benefits of...gan Comprehensive Cancer Center created a decision...
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2
...Hospitalist Company, Inc. (Nasdaq: IPCM ), a lea...nounced today that management is scheduled to pres...ference, which will be held on May 18th and 19th i...: 10:40 - 11:15 A.M. Eastern, ...
...,s Experts Featured In Film , , SAN FRANCISCO, Ma...to attend a FREE advance screening, ...mentary, film from HBO Documentary... internationally renowned, Alzheim...
...cans Month, the American Foundation for the Blind ...nting dangerous, unintentional falls among seniors...ericans Month -- " Living Today for a Better Tom...s have better health as they age and avoid the ris...
... Immune Deficiency Foundation , , LAS VEGAS and ...d a mold-ridden home that threatened their lives, ... of whom are diagnosed with Combined Immune Defici...e than 150 different primary immunodeficiency dise...
...hance Your Daily Routine , , , HUNT VALLEY, Md.,...ople to eat more healthfully and exercise to get i...utine can seem overwhelming. That,s why the "small...force of the American Society for Nutrition, Insti...
...division of global child health at Case Western Re...ive parents not to rely solely on vaccination reco...ldren,s immunizations. In the study, "Predictive V...D., M.S., and her colleagues examined immunization...
Other Medicine News:Health News:IPC The Hospitalist Company, Inc. to Present at Deutsche Bank's 34th Annual Health Care Conference 2Health News:HBO, the Arizona Alzheimer's Consortium and the Alzheimer's Association, Desert Southwest Chapter Present a Free Advance Screening of THE ALZHEIMER'S PROJECT: Momentum In Science 2Health News:Preventing Dangerous Slips and Falls: The American Foundation for the Blind Launches New Video Series on Staying Safe at Home 2Health News:ABC's 'Extreme Makeover: Home Edition' Helps Family Coping with Primary Immunodeficiency Disease 2Health News:ABC's 'Extreme Makeover: Home Edition' Helps Family Coping with Primary Immunodeficiency Disease 3Health News:Simple Steps Toward a Healthy Lifestyle 2Health News:Simple Steps Toward a Healthy Lifestyle 3Health News:Parents of internationally adopted children advised to verify children's immunization levels 2
Harms Corneal Utility Forceps, Colibri Style
Demarres Chalazion Forceps - 16 mm
Gradle Cilia Forceps
Hunt Chalazion Forceps
Medicine Products: